Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

GSK antiangiogenic Tie-2 and/or VEGFR2 inhibitors covered by patent

Oct. 13, 2003

Acceptable toxicity profile described for GEM-231 against refractory solid tumors

Oct. 10, 2003

ILX-651 enters new phase II study in melanoma

Oct. 10, 2003

Novel heparanase inhibitors and their use as antitumor agents described in recent patent

Oct. 9, 2003

News-breaking molecule: the first and only reported potent inhibitor of human asparagine synthase

Oct. 9, 2003

Antitumor efficacy and safety of arzoxifene in advanced endometrial cancer

Oct. 8, 2003

Sequential combination therapy reported effective in advanced follicular lymphoma

Oct. 8, 2003

Arius and PDL enter cancer antibody development partnership

Oct. 6, 2003

Rolling NDA submission continues for RSR-13

Oct. 6, 2003

Bayer presents two novel series of antitumor agents in recent patent literature

Oct. 6, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.